MedTrace Logo

Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

NCT03809429 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 437

Last updated 2024-05-13

Study results available
· View outcomes & findings →

Summary

To compare the efficacy and safety of FE 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) using a long gonadotropin-releasing hormone (GnRH) agonist protocol versus a short GnRH antagonist protocol.

Conditions

  • Infertility, Female

Interventions

DRUG

FE 999049 + GnRH agonist (GONAPEPTYL)

Pre-filled injection pen

DRUG

FE 999049 + GnRH antagonist (CETROTIDE)

Powder and solvent for solution for injection

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Compliance · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-29
Primary Completion
2022-02-16
Completion
2022-02-16

Countries

  • Austria
  • Denmark
  • Israel
  • Italy
  • Netherlands
  • Norway
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809429 on ClinicalTrials.gov